AlphaCrest Capital Management’s Acceleron Pharma XLRN Stock Holding History

AlphaCrest Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,930	Closed	-$1.62M	–	1433
2021 Q2	$1.62M	Buy	+12,930	New	+$1.63M	0.07%	446
2021 Q1	–	Sell	-4,036	Closed	-$516K	–	1357
2020 Q4	$516K	Buy	+4,036	New	+$473K	0.04%	631
2020 Q3	–	Sell	-2,594	Closed	-$247K	–	1227
2020 Q2	$247K	Sell	2,594 -2,379	-48%	-$229K	0.04%	728
2020 Q1	$447K	Sell	4,973 -6,727	-57%	-$523K	0.05%	623
2019 Q4	$620K	Sell	11,700 -7,100	-38%	-$324K	0.05%	643
2019 Q3	$743K	Buy	18,800 +4,100	+28%	+$178K	0.05%	715
2019 Q2	$604K	Buy	+14,700	New	+$609K	0.05%	625

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

AlphaCrest Capital Management's XLRN Position: Q3 2021 in Review

AlphaCrest Capital Management sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 12,930 shares — an estimated $1.62M sold.

AlphaCrest Capital Management first reported a position in XLRN in Q2 2019 and held it in 7 quarters. The position peaked at $1.62M in Q2 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

AlphaCrest Capital Management reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
AlphaCrest Capital Management sold 12,930 Acceleron Pharma shares in Q3 2021, an estimated $1.62M.
AlphaCrest Capital Management first reported a position in Acceleron Pharma in Q2 2019 and held it in 7 quarters.
AlphaCrest Capital Management's Acceleron Pharma position peaked at $1.62M in Q2 2021.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on AlphaCrest Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.